Comparative Pharmacology
Head-to-head clinical analysis: BLOXIVERZ versus EXELON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLOXIVERZ versus EXELON.
BLOXIVERZ vs EXELON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLOXIVERZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the serotonin transporter (SERT), leading to increased extracellular serotonin levels.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
10 mg intravenously every 12 hours; may increase to 15 mg every 12 hours based on clinical response.
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
None Documented
None Documented
Terminal half-life 18 hours (range 14-22 h); clinical: steady state in ~3.5 days, dosing adjustments needed in renal impairment.
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other routes.
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor